53
Participants
Start Date
February 28, 2009
Study Completion Date
February 28, 2011
Combination ipratropium/salbutamol or placebo (nebulization)
The COPD patients were randomly assigned a combination of ipratropium/salbutamol or a placebo in a double-blind crossover design. The bronchodilation produced by the medication was given in order to evaluate if bronchodilation was effective in increasing exercise tolerance during an endurance shuttle walking test in patients with GOLD stage I COPD.
Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Québec
Collaborators (2)
Boehringer Ingelheim
INDUSTRY
Pfizer
INDUSTRY
Laval University
OTHER